Dana Farber Cancer Institute SC-2

Boston, Massachusetts 02215

0 studies enrolling now · 3 studies all time

What they study most

3rd Line GIST, Islet Cell Tumor, Solid Tumor With p53 Wild Type Status

Studies at this site

• A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors — Completed
• A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients — Completed
• Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET — Stopped early